P. H. M. van der Kuy

TL;DR: This study shows that vaccinated individuals retain T cell immunity to the SARS-CoV-2 Omicron variant, potentially balancing the lack of neutralizing antibodies in preventing or limiting severe COVID-19 cases.

TL;DR: In this series, patient empowerment and registration of treatment outcomes delineated biosimilar transition, an approach that hypothetically could reduce nocebo response rates which are relevant to account for regarding biosimilar implementation is described.

TL;DR: Homologous or heterologous booster vaccination resulted in higher levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses than a single Ad26.COV2.S vaccination, and the strongest responses occurred after boosting with mRNA-based vaccines.

TL;DR: There is much heterogeneity in incidence and definitions for both medication related hospital admissions and readmissions, with known interventions being the involvement of a pharmacist, education programs and transition-care interventions the most mentioned ones although controversial results have been reported.

TL;DR: Medication review performed by a geriatrician, outpatient pharmacist, and Clinical Decision Support System provides different insights and should be combined to create a more comprehensive report on medication profiles.